Airway fibrosis
Conditions
Interventions
Control group:Conventional airway interventional therapy
Pirfenidone treatment group:Conventional airway intervention + pirfenidone
Sponsors
The First Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 70 years; 2. Patients with benign fibrous scar hyperplasia in the central airway after IV-type tracheal-bronchial tuberculosis, tracheal intubation/tracheal incision, and stent placement in the past 12 months; 3. Voluntary admission to airway intervention and 24 weeks of pirfenidone treatment.
Exclusion criteria
Exclusion criteria: 1. Poor compliance, refusal to receive airway interventional therapy and pirfenidone treatment; 2. The presence of contraindications to pirfenidone such as patients with toxic liver disease, severe renal dysfunction or need to dialysis patients, taking fluvoxamine; 3. Combined with serious primary diseases such as cardiovascular, liver, kidney and hematopoietic system, mental patients and serious diseases affecting their quality of life; 4. Patient Mycobacterium tuberculosis (+); 5. Type I, II, III, VI tracheobronchial tuberculosis; 6. Nintedanib, local injection of triamcinolone acetonide, paclitaxel-washing stent or intra-airway radiotherapy and other drugs that inhibit scar hyperplasia; 7. Subjects who are participating in other drug clinical trials or intervention studies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| stability of the two groups of fibrous scar hyperplasia; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in the degree of central airway stenosis;Reduction of sputum retention;Number of obstructive pneumonias;Changes in dyspnea index (mMRC);Changes in lung function;6 minutes walking distance change;SGRQ; | — |
Countries
China
Contacts
Public ContactGuo Shuliang
The First Affiliated Hospital of Chongqing Medical University
Outcome results
None listed